VM:CC - Voyageur Pharmaceuticals Partners with Rain Cage Carbon to Revolutionize Medical Imaging with Nanocarbon-Based Contrast Drugs

(TheNewswire)

Click Image To View Full Size

Calgary, Canada – TheNewswire- May 24, 2023 - Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) ( OTC :VYYRF) ("Voyageur" or the"Corporation"), announces it has entered into agroundbreaking  development and license agreement with Rain CageCarbon Inc. ("Rain Cage"). This strategic partnership aimsto revolutionize the field by developing and manufacturingcutting-edge nanocarbon/fullerene-based contrast agents for medicalimaging, utilizing Rain Cage’s innovative EDEN™ carbon capturetechnology.

By harnessing the unique properties of nanocarbonsproduced by the EDEN™ system, Voyageur is committed to creatingsafer and more advanced contrast agents for medical imaging. Theencapsulation and transporting of contrast agents within nanocarbonswill significantly enhance efficacy and safety for patients. Rain Cageis currently developing multiple molecules for contrast imaging, andthrough this agreement, Voyageur secures the rights to developfullerene-based imaging agents for the United States and Canadainitially. Expansion plans worldwide are expected to follow asdevelopment milestones are achieved and production capacityincreases.

Management of Voyageur believes Rain Cage has achieveda significant technological breakthrough with the pioneering EDEN™system, a truly exceptional technology capable of directly capturingCO 2 and various otheroxides from industrial emissions. Notably, this system transformsthese emissions into advanced engineered carbon material, a crucialcomponent for product development across various industries.

One of the innovative materials produced by RainCage’s system is fullerene, known for its high chemical stability,encapsulation ability, bio-compatibility, resistance to degradationand its ability to enhance contrast. These fullerenes serve as anideal foundation for radiology imaging contrast applications. In anexciting collaboration, Voyageur plans to leverage this nanocarboninnovation to create carbon-neutral, distinctive, and safer contrastagents. These agents are expected to play a vital role in clearlydelineating specific body areas during radiological examinations.

The employment of Rain Cage’s low-energy technologyto produce distinct carbon allotropes opens up new possibilities. Thistechnology provides Voyageur with an unprecedented opportunity todevelop innovative drugs that were previously hindered by cost andproduction considerations. With access to this innovative technology,Voyageur expects to differentiate itself apart in the industry.

In today's global market, carbon neutrality has becomeparamount, as organizations across industries acknowledge the urgentneed to address climate change and reduce greenhouse gas emissions.The pharmaceutical sector plays a critical role in building asustainable future by developing life-saving medications, whileminimizing environmental impact. By deploying carbon capturetechnology on our projects and manufacturing carbon-neutral products,Voyageur not only upholds its long-standing commitment tosustainability but also enhances brand reputation and competitivenessin the global market. As consumers increasingly prioritizeenvironmentally responsible solutions, Voyageur being recognized bythe investment community and by our customers as a carbon-neutralpharmaceutical company, aligns perfectly with globalexpectations.

This landmark agreement with Rain Cage marks asignificant milestone in Voyageur's journey, and we are excited toembark on this transformative path with Rain Cage.

Expressing his enthusiasm, Voyageur CEO Brent Willishighlights the disruptive potential of Rain Cage's fullerenes in themedical imaging market, stating, "This advanced technology hasremarkable properties that may revolutionize the way contrast agentsare currently used for medical imaging. I am delighted by theexecution of this agreement, which not only positions our Company atthe forefront of this innovative technology but also solidifies ourfuture as a carbon neutral pharmaceutical company by utilizing EDEN™technology. Through our partnership with Rain Cage, we will developand manufacture innovative new imaging products while maintaining ourunwavering dedication to protecting the environment, improving globalhealth, and leaving a positive legacy for futuregenerations."

Rain Cage and Voyageur are finalizing two additionalagreements to define a royalty structure for Rain Cage on sales of newfullerene-based drugs and establish an equipment deployment agreementfor utilizing Rain Cage carbon capture equipment and fullerene drugmanufacturing equipment. In addition, Voyageur is working with RainCage on monetizing carbon credits, providing an additional revenuestream to strengthen the Corporation's financial position movingforward. By implementing the EDEN™ technology into our futureproduction of imaging products, continuing to advance our social andgovernance goals, will allow Voyageur to meet its ESG mandates.

About Voyageur PharmaceuticalsLtd.

Voyageur, a Canadian public company trading under thesymbol VM on the TSXV, is in development of barium, iodine and carbonActive Pharmaceutical Ingredients (API) and high-performance,cost-effective imaging contrast agents. With a strategic focus onvertically integrating the barium, iodine and carbon contrast imagingmarket, Voyageur aims to become a key player by producing its ownbarium, iodine, and fullerene minerals.

Our business plan is set to generate immediate cashflow by partnering with established third-party GMP pharmaceuticalmanufacturers in Canada, ensuring the validation of our products byregulatory agencies worldwide. As we solidify our presence in themarket, we will transition into a high-margin domestic manufacturer ofradiology drugs, further expanding our revenue streams.

Voyageur is committed to sustainability andenvironmental stewardship. We envision a future where carbonneutrality is the norm, and to achieve this, we are buildingstate-of-the-art carbon-neutral infrastructure. By investing in carbonneutral energy sources and sustainable manufacturing practices, we aimto become 100% self-sufficient across all our manufacturingactivities. Our unwavering commitment to the environment sets us apartas a pioneer in the industry.

At the core of our operations, Voyageur owns a 100%interest in two barium sulphate (barite) projects, including theprestigious Frances Creek property. Additionally, Voyageur holdsinterests in a high-grade iodine, lithium, and bromine brine projectsituated in Utah, USA, further bolstering our position in theindustry. Voyageur owns a 100% interest in two battery mineralprojects which focus on copper/zinc development.

Our ambitious vision is to become the first verticallyintegrated, carbon-neutral company in the  imaging contrast mediadrug market. By controlling all primary input costs, from the sourcingof raw materials to the final production, we ensure unmatched qualityand cost efficiency. With our revolutionaryapproach, we embody the motto of " From the Earth to the Bottle ," highlighting our commitment to responsible sourcingand manufacturing practices.

About Rain Cage Carbon Inc.

Rain Cage is a pioneering private Canadian companydedicated to decarbonizing industries by capturing CO 2 and other emissions and transformingthem into engineered carbon. Through its proprietary technology,EDEN™, it offers companies a groundbreaking solution to combatcarbon pollution. Rain Cage's unique approach not only helps mitigateemissions but also harnesses contaminating emissions and converts theminto a recyclable technology with countless applications.

For Further Information:

Neither the TSX Venture Exchange nor its Regulation ServicesProvider (as that term is defined in the policies of the TSX VentureExchange) accepts responsibility for the adequacy or accuracy of thisnews release.

Cautionary Statement Regarding “Forward-Looking”Information

This news release may containcertain forward-looking information and statements, including withoutlimitation, statements pertaining to: the entering into of the twoadditional agreements to define royalty structure and equipmentdeployment; the success of utilizing Rain Cage's EDEN TM carbon capture technology to convertwaste carbon dioxide into fullerene nano particles; the ability togenerate and profitably transfer carbon credits; the market forfullerene based contrast agents; the EDEN TM technology being carbon neutral; andavailability of financing. All statements included herein, other thanstatements of historical fact, are forward-looking information andsuch information involves various risks and uncertainties. There canbe no assurance that such information will prove to be accurate, andactual results and future events could differ materially from thoseanticipated in such information. A description of assumptions used todevelop such forward-looking information and a description of riskfactors that may cause actual results to differ materially fromforward-looking information can be found in the Company's disclosuredocuments on the SEDAR website at www.sedar.com. Voyageur does notundertake to update any forward-looking information except inaccordance with applicable securities laws.

Calgary, Canada – TheNewswire- May 24, 2023 - Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) ( OTC :VYYRF) ("Voyageur" or the"Corporation"), announces it has entered into agroundbreaking  development and license agreement with Rain CageCarbon Inc. ("Rain Cage"). This strategic partnership aimsto revolutionize the field by developing and manufacturingcutting-edge nanocarbon/fullerene-based contrast agents for medicalimaging, utilizing Rain Cage’s innovative EDEN™ carbon capturetechnology.

By harnessing the unique properties of nanocarbonsproduced by the EDEN™ system, Voyageur is committed to creatingsafer and more advanced contrast agents for medical imaging. Theencapsulation and transporting of contrast agents within nanocarbonswill significantly enhance efficacy and safety for patients. Rain Cageis currently developing multiple molecules for contrast imaging, andthrough this agreement, Voyageur secures the rights to developfullerene-based imaging agents for the United States and Canadainitially. Expansion plans worldwide are expected to follow asdevelopment milestones are achieved and production capacityincreases.

Management of Voyageur believes Rain Cage has achieveda significant technological breakthrough with the pioneering EDEN™system, a truly exceptional technology capable of directly capturingCO 2 and various otheroxides from industrial emissions. Notably, this system transformsthese emissions into advanced engineered carbon material, a crucialcomponent for product development across various industries.

One of the innovative materials produced by RainCage’s system is fullerene, known for its high chemical stability,encapsulation ability, bio-compatibility, resistance to degradationand its ability to enhance contrast. These fullerenes serve as anideal foundation for radiology imaging contrast applications. In anexciting collaboration, Voyageur plans to leverage this nanocarboninnovation to create carbon-neutral, distinctive, and safer contrastagents. These agents are expected to play a vital role in clearlydelineating specific body areas during radiological examinations.

The employment of Rain Cage’s low-energy technologyto produce distinct carbon allotropes opens up new possibilities. Thistechnology provides Voyageur with an unprecedented opportunity todevelop innovative drugs that were previously hindered by cost andproduction considerations. With access to this innovative technology,Voyageur expects to differentiate itself apart in the industry.

In today's global market, carbon neutrality has becomeparamount, as organizations across industries acknowledge the urgentneed to address climate change and reduce greenhouse gas emissions.The pharmaceutical sector plays a critical role in building asustainable future by developing life-saving medications, whileminimizing environmental impact. By deploying carbon capturetechnology on our projects and manufacturing carbon-neutral products,Voyageur not only upholds its long-standing commitment tosustainability but also enhances brand reputation and competitivenessin the global market. As consumers increasingly prioritizeenvironmentally responsible solutions, Voyageur being recognized bythe investment community and by our customers as a carbon-neutralpharmaceutical company, aligns perfectly with globalexpectations.

This landmark agreement with Rain Cage marks asignificant milestone in Voyageur's journey, and we are excited toembark on this transformative path with Rain Cage.

Expressing his enthusiasm, Voyageur CEO Brent Willishighlights the disruptive potential of Rain Cage's fullerenes in themedical imaging market, stating, "This advanced technology hasremarkable properties that may revolutionize the way contrast agentsare currently used for medical imaging. I am delighted by theexecution of this agreement, which not only positions our Company atthe forefront of this innovative technology but also solidifies ourfuture as a carbon neutral pharmaceutical company by utilizing EDEN™technology. Through our partnership with Rain Cage, we will developand manufacture innovative new imaging products while maintaining ourunwavering dedication to protecting the environment, improving globalhealth, and leaving a positive legacy for futuregenerations."

Rain Cage and Voyageur are finalizing two additionalagreements to define a royalty structure for Rain Cage on sales of newfullerene-based drugs and establish an equipment deployment agreementfor utilizing Rain Cage carbon capture equipment and fullerene drugmanufacturing equipment. In addition, Voyageur is working with RainCage on monetizing carbon credits, providing an additional revenuestream to strengthen the Corporation's financial position movingforward. By implementing the EDEN™ technology into our futureproduction of imaging products, continuing to advance our social andgovernance goals, will allow Voyageur to meet its ESG mandates.

About Voyageur PharmaceuticalsLtd.

Voyageur, a Canadian public company trading under thesymbol VM on the TSXV, is in development of barium, iodine and carbonActive Pharmaceutical Ingredients (API) and high-performance,cost-effective imaging contrast agents. With a strategic focus onvertically integrating the barium, iodine and carbon contrast imagingmarket, Voyageur aims to become a key player by producing its ownbarium, iodine, and fullerene minerals.

Our business plan is set to generate immediate cashflow by partnering with established third-party GMP pharmaceuticalmanufacturers in Canada, ensuring the validation of our products byregulatory agencies worldwide. As we solidify our presence in themarket, we will transition into a high-margin domestic manufacturer ofradiology drugs, further expanding our revenue streams.

Voyageur is committed to sustainability andenvironmental stewardship. We envision a future where carbonneutrality is the norm, and to achieve this, we are buildingstate-of-the-art carbon-neutral infrastructure. By investing in carbonneutral energy sources and sustainable manufacturing practices, we aimto become 100% self-sufficient across all our manufacturingactivities. Our unwavering commitment to the environment sets us apartas a pioneer in the industry.

At the core of our operations, Voyageur owns a 100%interest in two barium sulphate (barite) projects, including theprestigious Frances Creek property. Additionally, Voyageur holdsinterests in a high-grade iodine, lithium, and bromine brine projectsituated in Utah, USA, further bolstering our position in theindustry. Voyageur owns a 100% interest in two battery mineralprojects which focus on copper/zinc development.

Our ambitious vision is to become the first verticallyintegrated, carbon-neutral company in the  imaging contrast mediadrug market. By controlling all primary input costs, from the sourcingof raw materials to the final production, we ensure unmatched qualityand cost efficiency. With our revolutionaryapproach, we embody the motto of " From the Earth to the Bottle ," highlighting our commitment to responsible sourcingand manufacturing practices.

About Rain Cage Carbon Inc.

Rain Cage is a pioneering private Canadian companydedicated to decarbonizing industries by capturing CO 2 and other emissions and transformingthem into engineered carbon. Through its proprietary technology,EDEN™, it offers companies a groundbreaking solution to combatcarbon pollution. Rain Cage's unique approach not only helps mitigateemissions but also harnesses contaminating emissions and converts theminto a recyclable technology with countless applications.

For Further Information:

Neither the TSX Venture Exchange nor its Regulation ServicesProvider (as that term is defined in the policies of the TSX VentureExchange) accepts responsibility for the adequacy or accuracy of thisnews release.

Cautionary Statement Regarding “Forward-Looking”Information

This news release may containcertain forward-looking information and statements, including withoutlimitation, statements pertaining to: the entering into of the twoadditional agreements to define royalty structure and equipmentdeployment; the success of utilizing Rain Cage's EDEN TM carbon capture technology to convertwaste carbon dioxide into fullerene nano particles; the ability togenerate and profitably transfer carbon credits; the market forfullerene based contrast agents; the EDEN TM technology being carbon neutral; andavailability of financing. All statements included herein, other thanstatements of historical fact, are forward-looking information andsuch information involves various risks and uncertainties. There canbe no assurance that such information will prove to be accurate, andactual results and future events could differ materially from thoseanticipated in such information. A description of assumptions used todevelop such forward-looking information and a description of riskfactors that may cause actual results to differ materially fromforward-looking information can be found in the Company's disclosuredocuments on the SEDAR website at www.sedar.com. Voyageur does notundertake to update any forward-looking information except inaccordance with applicable securities laws.

Copyright (c) 2023 TheNewswire - All rights reserved.